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Abstract
BACKGROUND: Women with a history of differentiated thyroid 
carcinoma who are contemplating pregnancy may wish reas-
surance regarding apparent remission. However, the thyroid 
hormone withdrawal needed to obtain serum thyroglobulin 
testing (Tg) results in weeks-long biochemical and clinical hy-
pothyroidism, which could increase miscarriage and fetal death 
rates if pregnancy occurred during withdrawal of thyroxine or 
soon thereafter. Recombinant human thyrotropin (rhTSH) ele-
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vates thyrotropin exogenously, allowing uninterrupted thyroid 
hormone therapy and avoids hypothyroidism.
MATERIAL AND METHODS: Thirty female radiation-induced 
papillary thyroid carcinoma survivors who had undergone 
total- or near-total thyroidectomy and who were now seeking 
pregnancy (mean age 23.9 ± 1.8 years), and who were consid-
ered cancer-free by local standards, underwent rhTSH-aided Tg 
testing to help confirm remission. At the time of rhTSH testing, 
mean follow-up after primary surgical treatment was 11.1 ± 
3.9 years, and all patients had negative neck ultrasonography, 
undetectable unstimulated serum Tg (< 0.2 ng/mL) and no 
interfering anti-Tg antibodies. However, based on T3, N1 or M1 
status, 28/30 (93.3%) patients had high recurrence risk.
RESULTS: rhTSH produced no serum Tg increase in 27/30 
women (90.0%). Serum Tg increases to 0.4-0.9 ng/ml were 
observed in 3 women, but careful neck ultrasonography found 
no lymphadenopathy. Reassured about their remission, 14/30 
women (46%) have become pregnant and delivered healthy 
children in the 3 years since rhTSH-aided testing.
CONCLUSIONS: rhTSH-aided Tg testing is useful in confirming 
absence of tumor in female patients with a history of radiation-in-
duced thyroid cancer who are seeking pregnancy, but who also 
have a high risk of thyroid cancer recurrence.
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Background
Dramatically increased differentiated thyroid carcinoma (DTC) 
incidence in the young was the greatest public health consequence 
of the 1986 Chernobyl nuclear reactor disaster. By 2006, nearly 
5,000 DTC cases had been diagnosed among the population that 
was ≤ 18 years old at the time of the accident. Fortunately, although 
radiation-induced DTC shows aggressive properties including 
frequent metastasis, even in young patients with advanced tumors, 
treatment has been highly effective and cure frequent [1–3].
Therefore, a unique situation occurs in Belarus, where a large 
number of young reproductive-age women is under endocrinolo-
gists’ observation because of a DTC history. Because of the high 
recurrence risk in patients apparently cured of advanced disease, 
these women receive long-term follow-up generally including 
periodic physical examination, neck ultrasonography (US), se-
rum thyroglobulin (Tg) measurement using modern assays and 
whole-body scintigraphy (WBS). For optimal sensitivity, the latter 
two procedures require serum thyrotropin elevation [3–5]. In 
this (near) totally-thyroidectomized population, such elevation 
is attained through thyroid hormone withdrawal (THW) rather than 
through recombinant human thyroid-stimulating hormone (rhTSH) 
administration which, due to limited financial resources, has not 
been readily available in Belarus [3].
Pregnancy appears to stimulate normal thyroid growth as well 
as Tg production, and is a state of reduced immune function 
[6–9]. Additionally, although data on this possible relationship are 
conflicting [3, 7, 9–13], increased estrogen concentrations have 
been postulated to play a role in thyroid cancer growth [14]. It 
thus is reasonable for DTC survivors planning to have children, 
as well as their physicians, to be concerned that pregnancy may 
be associated with an increased risk of DTC recurrence or pro-
gression [7, 15]. 
Reports [6, 8] exist that DTC survivors who are apparently 
free of recurrence can become pregnant without any unfavorable 
impact on their course. Therefore, it is desirable in patients plan-
ning pregnancy to obtain reassurance of cure, or to detect and 
eliminate any residual disease, before pregnancy is attempted. 
However, the THW needed to stimulate Tg testing and WBS 
results in weeks-long biochemical and most often also clinical 
hypothyroidism, and even minimal hypothyroidism can increase 
miscarriage and fetal death rates and also may adversely affect 
the offspring’s cognitive development [6, 12, 16, 17].
As an exogenous source of TSH, rhTSH prevents from interrup-
tion of thyroid hormone therapy, and hence, hypothyroid metabolic 
impairment or morbidity, entailed by raising TSH endogenously 
with THW. Therefore when the manufacturer donated 30 rhTSH 
kits to our center, the concept emerged to apply those kits to 
aid follow-up examinations confirming the disease-free status of 
young Chernobyl-induced DTC survivors who were attempting to 
become pregnant. Although rhTSH has been used in hundreds of 
thousands of adults [10, 11, 18, 19] and some juveniles [20], 
limited data have been published regarding rhTSH use in young 
patients with radiation-induced DTC. For that reason, we undertook 
this retrospective analysis of our single-center experience with 
rhTSH stimulation of diagnostic procedures to rule out disease in 
members of this group who were planning pregnancy. 
Materials and methods
Patients
This cohort analysis involved 30 consecutive eligible 
patients followed at the National Dispensary of Medical Re-
habilitation and Hydrotherapy in Minsk, Belarus. Selected 
patient characteristics are seen in Table 1; based on T3, N1 or 
M1 status, 28/30 patients (93.3%) were considered to be at high 
recurrence risk. Inclusion criteria for the rhTSH-aided diagnostic 
Table 1. Selected characteristics of 30 female thyroid cancer 
patients
Characteristic Value
Age at rhTSH-aided testing, years
Mean ± SD 23.9 ± 1.8 
Median (range) 23.6 (20–29)
Age at time of Chernobyl accident, years
Mean ± SD 1.6 ± 1.6
Median (range) 1.2 (0–7)
T stagea
T1 20
T2 7
T3 3
N stagea  
N0 2
N1a 9
N1b 19
M stagea  
M0 27
M1 3
Number of prior radioiodine therapies, % (n) of patients
1 27% (8)
2 47% (14)
3 17% (5)
≥ 5 10% (3)
Cumulative therapeutic radioiodine activity, GBq
Mean ± SD 8.9 ± 6.1
Median (range) 7.2 (2.2–29.3)
Daily LT4 dose at time of study entry  
Mean ± SD, µg/kg 2.6 ± 0.6 
On >3 µg/kg, % (n) 10% (3)
On calcium therapy, % (n) 50% (15)
Interval disease-free at time of rhTSH-aided testing, years
Mean ± SD 7.7 ± 3.6 
Median (range) 7.8 (3.5–17)
Live births before rhTSH-aided testing, % (n) of patients
0 77% (23)
1 23% (7)
DTC — differentiated thyroid carcinoma; LT4 — levothyroxine; SD — standard 
deviation; TNM — tumor, nodes, metastasis; aTNM according to the American Joint 
Committee on Cancer/Union Internationale Contre le Cancer classification of 2002
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procedures were: near-term plans to become pregnant; his-
tory of histologically-proven, radiation-induced DTC; (near-) total 
thyroidectomy with neck lymph node dissection; and > 1 yr 
interval since the last therapeutic radioiodine activity. Moreover, 
patients had to have no evident residual DTC according to these 
criteria: no pathological uptake outside the thyroid bed on WBS 
performed ≤ 1 yr before the rhTSH-aided procedures; undetect-
able (< 0.2 ng/mL) unstimulated serum Tg or stimulated serum 
Tg levels < 1 ng/ml ≥ 6 months before the procedures; absence 
of interfering Tg antibodies (TgAb) at the time of the procedure; 
no clinical or US signs of residual disease at the time of the 
rhTSH-aided testing. 
Patients were given rhTSH (Thyrogen, thyrotropin alfa, Gen-
zyme, Cambridge, MA, USA), 0.9 mg, by intramuscular injection 
on 2 consecutive days while on levothyroxine therapy. Blood 
samples were drawn on day 1 (“baseline,” immediately before 
the first rhTSH injection), day 3 (1 day after the second rhTSH 
injection) and day 5 (3 days after the second rhTSH injection) for 
determination of serum TSH, Tg, TgAB, and anti-thyroperoxidase 
(TPO) antibody levels. 
TSH was quantified by radioimmunoassay (DPC, Biermann, 
Germany; normal range in healthy adults: 0.3–4.0 mIU/l). Serum Tg 
was measured with an immunoradiometric assay (Thermo Fisher 
B.R.A.H.M.S., Henningsdorf, Germany). The assay has a functional 
sensitivity of 0.2 ng/ml; results lower or equal to this level were 
considered undetectable, but were reported as 0.2 ng/ml. TgAb 
and anti-TPO autoantibodies were evaluated by enzyme immu-
noassay (Phadia Pharmacia, Freiburg, Germany), with negative 
values defined as < 100 IU/ml. Quality control of all biochemical 
testing was done at the Department of Nuclear Medicine, Wurzburg 
University, Würzburg, Germany. 
All patients gave informed consent for rhTSH-aided testing, 
and the protocol for such testing was approved by our Institutional 
Review Board.
Results 
Table 2 presents mean values for all tested analytes.
TSH
Twenty-seven of 30 patients (90%) had suppressed base-
line TSH (0.01-0.09 mIU/l); the remaining three had TSH of 1.6 
– 4.0 mIU/l. TSH rose on average nearly 1600-fold the day after 
the rhTSH course, ranging from 46.0-227.2 mIU/l; 2 days later, the 
analyte had sharply decreased (by 90.9%) from the day 3 eleva-
tions, and ranged from 10.2 ± 4.3 mIU/l.
Tg
All 30 patients had undetectable baseline Tg (≤ 0.2 ng/ml). 
Serum Tg increased slightly after rhTSH stimulation in 3 pa-
tients (Figure 1): 
 — patient A, age 24 yr, had a 3.5-yr follow-up after apparent cure 
of T3/N1/M1 disease, and stimulated Tg of 0.9 ng/ml on day 5 
(Cumulative therapeutic radioiodine activity 6,2 GBq);
 — patient F., age 23 yr, had T1/N1/M0 disease, a 15.5-yr follow-up, 
and stimulated Tg of 0.7 ng/ml on day 5 (Cumulative thera-
peutic radioiodine activity 5,2 GBq);
 — patient G. age 23 yr, had T3/N1/M1 disease, a 15-yr follow-up, 
and stimulated Tg levels 0.4 ng/ml on day 5 (Cumulative 
therapeutic radioiodine activity 20,1 GBq).
None of these three patients had lymphadenopathy on neck 
US, and an additional measurement of serum Tg (on levothyroxine) 
in next 3 months was recommended. 
TgAb and anti-TPO antibodies
In all 30 patients, TgAb and anti-TPO antibody titers were well 
below levels considered detectable both before and after the 
rhTSH course. 
rhTSH tolerability
RhTSH-aided testing had no serious side effects, however 2 
patients complained of some headache during investigation and 
2 others had nausea.
Patients’ courses and pregnancies since  
rhTSH-aided testing
The entire cohort has been re-evaluated regularly by physical 
exams, US, and unstimulated Tg testing during the 3 years after 
the rhTSH test. No patient demonstrated any evidence of disease 
in the time since the rhTSH-aided testing. Only one patient showed 
elevated titer TgAb antibodies after delivery of an infant.
Table 2. Serum TSH, Tg, TgAb and anti-TPOAb levels before and 
after rhTSH stimulation in 30 radiation-induced DTC survivors 
planning pregnancy
Analyte Day 1 Day 3 Day 5
(baseline; 
immediately 
before 1st rhTSH 
injection)
(1 day after 2nd 
rhTSH injection)
(3 days after 2nd 
rhTSH injection) 
Mean ± SD
TSH, mIU/l 0.07 ± 0.1 111.5 ± 37.1 10.2 ± 4.3
Tg, ng/ml 0.2a ± 0.0 0.2a ± 0.0 0.2a ± 0.1
TgAb, IU/lb 36.0 ± 20.8 Not measured 9.4 ± 14.5
TPOAb, IU/lb 18.6 ± 15.3 Not measured 18.7 ± 13.1
DTC — differentiated thyroid cancer; rhTSH — recombinant human thyroid-
stimulating hormone; SD — standard deviation; Tg — thyroglobulin; TgAb 
— anti-thyroglobulin autoantibodies; TPO — thyroperoxidase; TPOAb — anti-
thyroperoxidase antibodies; TSH — thyroid-stimulating hormone; aundetectable 
values (< 0.2 ng/ml were reported as 0.2 ng/ml, the functional assay sensitivity; btiters 
< 100 IU/l were considered undetectable
Figure 1. Individual serum Tg levels before and after rhTSH stimula-
tion in 30 female radiation-induced DTC survivors
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In that interval, 16/30 (53.3%) women became pregnant, of 
whom 14/30 (46.6%) delivered a healthy child after an uneventful 
pregnancy, 2/30 (6.6%) had a miscarriage during early gestation, 
and 2/30 (6.6%) had a tubal pregnancy. Note that numerators add 
to more than 30 due to two events in some women. Among the live 
births, no congenital malformations or first year neonatal mortality 
was observed.
Regarding 3 patients with slightly increased serum Tg after 
rhTSH stimulation, none demonstrated any elevated Tg level (on 
levothyroxine) during subsequent follow-up. Two women delivered 
a healthy child. Patient A experienced a tubal pregnancy followed 
by a pregnancy that resulted with a healthy child. Patient G experi-
enced a miscarriage in early gestation followed by a pregnancy that 
resulted with a healthy child. Patient F is still seeking pregnancy.
Two women underwent surgical intervention because one of 
them had ovarian cysts and endometriosis, while the other was 
diagnosed with craniapharyngioma and developed hypopituitarism 
after surgery.
Two additional women were under treatment for infertility. The 
other 8 women are still trying to become pregnant.
Discussion
The peak in radioinduced thyroid cancer incidence occurred in 
the early 1990’s in Belarus, Ukraine and Russia after environmental 
contamination with radioactive iodine from the 1986 Chernobyl 
nuclear power plant catastrophe [1–3]. The accelerated onset of 
thyroid cancer may be attributable to radiation dose rate effects, 
sensitivity to the effects of ionizing radiation during early childhood, 
screening activity that enhanced case finding, and to endemic 
iodine deficiency in Eastern Europe [1, 11, 21]. 
The cohort of children and adolescents with radiation-induced 
thyroid cancer is currently entering the period of reproductive 
activity and child-bearing age [22]. Because of the propensity of 
juvenile DTC to spread aggressively, such patients are usually at high 
relapse risk and have been exposed to radioiodine therapy [2, 3]. 
These cancer survivors should have special medical considera-
tions as they contemplate pregnancy. It would be valuable in young 
women believed likely to be free of thyroid cancer to confirm the 
absence of tumor before they become pregnant, and to perform 
this assessment without a long period of hypothyroidism during 
the time of pregnancy planning [6]. Prolonged hypothyroidism 
is related to exacerbation of concomitant illnesses or stimula-
tion of tumor growth. Use of rhTSH to provide TSH stimulation 
exogenously allows to avoids many of these problems [4, 10, 18].
Recent studies suggest that in patients without apparent recur-
rence, pregnancy has no unfavorable health impact [6, 8, 15]. No 
restriction concerning seeking pregnancy exists when the following 
criteria are met: last iodine-131 treatment ≥ 12 months prior, normal 
clinical exam, normal neck US within 6 months prior, stimulated 
Tg < 2 ng/mL in the absence of known persistent or recurrent 
disease, or a > 50% decrease from peak Tg in conjunction with 
negative imaging in patients previously treated for metastases, 
TSH < 2.0 mIU/L [8, 10, 12]. In addition, ideally a woman will 
have favorable socioeconomic conditions that permit specialized 
follow-up, among other reasons to titrate the levothyroxine dose 
as needed to avoid hypothyroidism should pregnancy occur. As-
suring that these criteria are met is particularly important in many 
young women who have persistent subclinical disease detected 
by highly sensitive Tg assays and neck US. Such low levels of 
serum Tg can be difficult to eradicate with additional radioactive 
iodine therapy or surgery [8].
The experience reported here demonstrates the effectiveness of 
using rhTSH to obtain further reassurance of the disease-free 
status of young women with a history of radiation-induced DTC 
who are planning pregnancy, while avoiding the hypothyroidism 
of THW. To confirm apparent cure, one should not rely simply on 
unstimulated Tg levels, since false negative Tg measurements us-
ing second-generation assays have been reported in about 20% 
of patients with isolated neck lymph node metastases and in 5% 
with small distant metastases, mainly in the lungs and not visible 
on X-rays [12, 14, 15].
In this study we observed that in period of 3 years (2009–2011) 
14 of 30 women delivered a healthy child (46.6%) and 4/30 (13.3%) 
lost their pregnancy. We should emphasize that the majority of our 
patients (28 of 30) belonged to high risk group regarding possible 
tumor recurrence. Thus, testing of these women to be more certain 
of their tumor-free status prior to pregnancy was important.
In conclusion, rhTSH-aided Tg testing is useful in helping to 
better confirm absence of thyroid cancer in female thyroid cancer 
survivors who are seeking pregnancy. This might be particularly im-
portant in women with a history of radiation-induced thyroid cancer 
who are thought to have a high risk of thyroid cancer recurrence.
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